Trulieve Announces September 2021 Investor Conference Participation
TALLAHASSEE, FL, Sept. 7, 2021 /PRNewswire/ - Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States, today announced that CEO Kim Rivers will be participating in various investor conferences in September.
- Beacon Securities Virtual Cannabis Conference, September 9, 2021: Ms. Rivers will participate in a fireside chat at 1:00 p.m. ET and one-on-one meetings.
- Needham Virtual Cannabis Conference, September 14, 2021: Ms. Rivers will participate in a fireside chat at 3:45 p.m. ET and one-on-one meetings.
- BTIG Virtual Inaugural Cannabis Conference, September 29, 2021: Ms. Rivers will participate in a fireside chat at 1:05 p.m. ET and one-on-one meetings.
About Trulieve
Trulieve is primarily a vertically integrated "seed-to-sale" company in the U.S. and is the first and largest fully licensed medical cannabis company in the State of Florida. Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida, as well as directly to patients via home delivery. Trulieve also holds licenses to operate in California, Massachusetts, Pennsylvania, Connecticut, and West Virginia. Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF.
To learn more about Trulieve, visit www.Trulieve.com.
The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.
View original content:https://www.prnewswire.com/news-releases/trulieve-announces-september-2021-investor-conference-participation-301369759.html
SOURCE Trulieve Cannabis Corp.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Swanson Vitamins Launches Swanson Vitamins Nexus Pro to Champion Registered Dietitians and Licensed Nutritionists at Every Stage of Their Careers
- Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026
- Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Needham & Company, BTIGSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share